GlyConnect

N-Linked / Complex (avg mass : 1114.0275)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

PREEQFNSTYR (11aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1317.2225)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1463.3655)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1479.3649)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1567.4278)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1625.5079)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1713.5708)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 1787.6503)

src (1) ref (1) site (1) pept (3)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

PREEQFNSTYR (11aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 2078.9082)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Complex (avg mass : 2370.1661)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / High-Mannose (avg mass : 1072.9749)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / High-Mannose (avg mass : 1235.1173)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / High-Mannose (avg mass : 1397.2597)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / High-Mannose (avg mass : 1559.4021)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / High-Mannose (avg mass : 1721.5445)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Hybrid (avg mass : 1438.3123)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Hybrid (avg mass : 1584.4553)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Hybrid (avg mass : 1600.4547)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Hybrid (avg mass : 1729.5702)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Hybrid (avg mass : 2037.8556)

src (1) ref (1) site (1) pept (1)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

N-Linked / Undefined core (avg mass : 1422.3129)

src (1) ref (1) site (1) pept (2)

Source

SK-BR-3 (CVCL_0033)

Reference

Malignant tissues produce divergent antibody glycosylation of relevance for cancer gene therapy effectiveness. (2020 - Brücher D, Franc V, Smith SN, Heck AJR, Plückthun A) / Status : Reviewed

Reported glycosite

Mass spectrometry observed peptide

EEQFNSTYR (9aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens
TKPREEQFNSTYR (13aa)
- Asn-177 Immunoglobulin heavy constant gamma 4 (nivolumab) / Homo sapiens

Cell line SK-BR-3

Taxonomy

Protein

Source

Reported structure

Composition

Disease

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference

Reported glycosite

Mass spectrometry observed peptide

Source

Reference